+61.9%
GSK vs NIO
-62.6%
+124.5%
-28.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | NIO | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.9% | -1.6% | -0.4% | -1.9% |
| 7D | -1.8% | -13.0% | +11.2% | -1.4% |
| 30D | -2.2% | -18.3% | +16.1% | -1.6% |
| 3M | -1.8% | -33.2% | +31.4% | -0.7% |
| 6M | -10.6% | -21.5% | +10.9% | -10.1% |
| YTD | +4.4% | -25.5% | +29.9% | +5.1% |
| 1Y | +30.4% | -38.0% | +68.4% | +31.7% |
| All | +61.9% | -62.6% | +124.5% | +63.0% |
Cumulative growth
Daily Returns
Daily percentage return beside NIO.
Daily Out/Under-Performance
Portfolio return minus NIO return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × NIO return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded NIO wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling